A number of other equities analysts have also weighed in on AZN. Shore Capital reiterated a hold rating on shares of Astrazeneca PLC in a research report on Wednesday, August 10th. Citigroup Inc. restated a buy rating on shares of Astrazeneca PLC in a research report on Wednesday, July 27th. Beaufort Securities restated a hold rating on shares of Astrazeneca PLC in a research report on Thursday, August 11th. JPMorgan Chase & Co. restated a neutral rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Finally, Piper Jaffray Cos. began coverage on shares of Astrazeneca PLC in a research report on Friday, September 23rd. They issued an overweight rating for the company. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Astrazeneca PLC has a consensus rating of Hold and a consensus price target of $37.56.
Astrazeneca PLC (NYSE:AZN) traded up 1.0046% during trading on Friday, reaching $30.8973. 6,624,223 shares of the company were exchanged. The company has a market capitalization of $78.17 billion, a P/E ratio of 35.3112 and a beta of 0.75. The firm’s 50-day moving average is $32.87 and its 200 day moving average is $30.88. Astrazeneca PLC has a one year low of $26.97 and a one year high of $35.04.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.07. The firm earned $5.60 billion during the quarter, compared to analyst estimates of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company’s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter last year, the business earned $1.21 earnings per share. On average, analysts anticipate that Astrazeneca PLC will post $2.97 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in AZN. Dodge & Cox boosted its stake in Astrazeneca PLC by 121.2% in the first quarter. Dodge & Cox now owns 26,049,650 shares of the company’s stock valued at $733,558,000 after buying an additional 14,272,518 shares during the period. Forester Capital Management LTD boosted its stake in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares during the period. Chubb Ltd. bought a new stake in Astrazeneca PLC during the first quarter valued at $14,080,000. Primecap Management Co. CA boosted its stake in Astrazeneca PLC by 1,223.1% in the first quarter. Primecap Management Co. CA now owns 13,084,275 shares of the company’s stock valued at $368,453,000 after buying an additional 12,095,375 shares during the period. Finally, Stockman Asset Management boosted its stake in Astrazeneca PLC by 11.3% in the first quarter. Stockman Asset Management now owns 62,700 shares of the company’s stock valued at $1,766,000 after buying an additional 6,380 shares during the period. Institutional investors and hedge funds own 11.46% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.